572922-91-9 Usage
Molecular weight
295.31 g/mol The mass of one mole of the compound, calculated from its molecular formula.
Functional groups
Carboxyl, Ester, Amino, and Hydroxyl The specific functional groups present in the compound that determine its chemical reactivity and properties.
Stereochemistry
(1R,2S) and (2S,4S) The specific spatial arrangement of the atoms in the molecule, which can affect its biological activity and interactions with other molecules.
Bityrosine derivative
A rare compound found in proteins and peptides The compound is derived from bityrosine, an uncommon amino acid that is formed through the oxidation of tyrosine.
Involvement in oxidative stress and inflammation
The compound is thought to be involved in these processes in the body, which can have implications for various diseases and conditions.
Pharmaceutical research and development
The compound has potential implications for pharmaceutical research, particularly in the study of protein structure and function, as it is a derivative of an amino acid that can affect these properties.
Check Digit Verification of cas no
The CAS Registry Mumber 572922-91-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,2,9,2 and 2 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 572922-91:
(8*5)+(7*7)+(6*2)+(5*9)+(4*2)+(3*2)+(2*9)+(1*1)=179
179 % 10 = 9
So 572922-91-9 is a valid CAS Registry Number.
572922-91-9Relevant academic research and scientific papers
HEPATITIS C INHIBITOR COMPOUNDS
-
Page/Page column 47, (2010/04/27)
Compounds of Formula (I): wherein B, R3, L0, L1, R2, Rc and R1 are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection. In particular, the present invention provides novel peptide analogs, pharmaceutical compositions containing such analogs, and uses of these analogs in the treatment of HCV infection
MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE
-
Page/Page column 74, (2010/04/25)
The invention provides macrocyclic compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically indicated, and methods of treatment of a Hepatitis C viral infection in a human patient.
HEPATITIS C INHIBITOR COMPOUNDS
-
Page 57-58, (2008/06/13)
Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
